pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$IOVAIOVANCE BIOTHERAPEUTICS, INC.

$IOVA8.9900+12.52%
San Carlos, CA, USupdated 8m ago

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
5
marketed
1
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(5)

pipeline depth5 products
Phase 2: 3Phase 3: 1Marketed: 1
3Phase 21Phase 31Marketed
Marketed
aldesleukin
Metastatic Renal Cell Carcinoma
Phase 3
lifileucel
Metastatic Melanoma
Phase 2
IOV-2001
Chronic Lymphocytic Leukemia (CLL)
Phase 2
IOV-4001
Metastatic Melanoma
Phase 2
LN-145
Non-Small Cell Lung Cancer

📅 Upcoming

Nov 5, 2026
earnings
$IOVA8.9900+12.52%
in 3mo
IOVANCE BIOTHERAPEUTICS, INC. earnings
IOVANCE BIOTHERAPEUTICS, INC.
→

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcomanot yet recruitingn=80
  • phase2A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanomaactive not recruitingn=100
  • —Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Releaseavailable
  • phase2Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancerrecruitingn=170
  • phase1Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participantsactive not recruitingn=40
  • phase3Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.recruitingn=670
  • phase2Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanomacompletedn=220
  • phase1Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLLcompletedn=7
more trials →

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Mar 9, 26grantGRAF FINCKENSTEIN FRIEDRICH · Chief Medical Officer58,750 sh
  • Mar 9, 26grantKirby Daniel Gordon · Chief Commercial Officer132,200 sh
  • Mar 9, 26grantBILINSKY IGOR · Chief Operating Officer117,500 sh
  • Mar 9, 26grantRoche Corleen M. · Chief Financial Officer132,200 sh
  • Mar 9, 26grantVogt Frederick G · Interim CEO & General Counsel235,000 sh
  • Mar 9, 26grantPuri Raj K. · Chief Regulatory Officer117,500 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
38 open roles at IOVANCE BIOTHERAPEUTICS, INC. →

Where IOVANCE BIOTHERAPEUTICS, INC. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 38
departmentManufacturing / CMC 9Regulatory 7Biostatistics / Data 5Supply Chain 4IT & Engineering 3Market Access 2

News

no news has mentioned this company yet
identifiers
ticker
$IOVA
SEC CIK
0001425205
country
US
source
sec_tickers
top tags
Oncology4NSCLC2
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 8m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?